rpcardioRational Pharmacotherapy in CardiologyРациональная Фармакотерапия в Кардиологии1819-64462225-3653«SILICEA-POLIGRAF» LLC10.20996/1819-6446-2022-06-02rpcardio-2744Research ArticleORIGINAL STUDIESОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯRisk of Venous Thromboembolic Complications in Patients with Atrial Fibrillation: a Systematic Review and Meta-analysisРиск венозных тромбоэмболических осложнений у пациентов с фибрилляцией предсердий: систематический обзор и мета-анализhttps://orcid.org/0000-0001-5938-8917СоколоваА. А.SokolovaA. A.

Соколова Анастасия Андреевна - eLibrary SPIN 2153-3542.

Москва

Anastasya A. Sokolova - eLibrary SPIN 2153-3542.

Moscow

https://orcid.org/0000-0003-0160-6015КудрявцеваА. А.KudriavtsevaA. A.

Кудрявцева Анна Александровна

Москва

Anna A. Kudriavtseva

Moscow

ankudr@bk.ruhttps://orcid.org/0000-0003-3509-7271КостиковаН. В.KostokovaN. V.

Костикова Нина Владимировна

Москва

Nina V. Kostokova

Moscow

https://orcid.org/0000-0001-8118-0522ЗаикинаМ. П.ZaikinaM. P.

Заикина Маргарита Павловна

Москва

Margarita P. Zaikina

Moscow

https://orcid.org/0000-0001-6901-5663ГебековаЗ. А.GebekovaZ. A.

Гебекова Зарема Алиосмановна

Москва

Zarema A. Gebekova

Moscow

https://orcid.org/0000-0001-6241-2711НапалковД. А.NapalkovD. A.

Напалков Дмитрий Александрович - eLibrary SPIN 2894-5010.

Москва

Dmitry A. Napalkov - eLibrary SPIN 2894-5010.

Moscow

https://orcid.org/0000-0002-6563-0471ЗолотухинИ. А.ZolotukhinI. A.

Золотухин Игорь Анатольевич - eLibrary SPIN 3426-2981.

Москва

Igor A. Zolotukhin - eLibrary SPIN 3426-2981

Moscow

Первый Московский государственный медицинский университет имени И.М. Сеченова (Сеченовский университет)РоссияI.M. Sechenov First Moscow State Medical University (Sechenov University)Russian FederationРоссийский национальный исследовательский медицинский университет имени Н.И. ПироговаРоссияPirogov Russian National Research Medical UniversityRussian Federation202206072022183236241Copyright © Sokolova A.A., Kudriavtseva A.A., Kostokova N.V., Zaikina M.P., Gebekova Z.A., Napalkov D.A., Zolotukhin I.A., 20222022Соколова А.А., Кудрявцева А.А., Костикова Н.В., Заикина М.П., Гебекова З.А., Напалков Д.А., Золотухин И.А.Sokolova A.A., Kudriavtseva A.A., Kostokova N.V., Zaikina M.P., Gebekova Z.A., Napalkov D.A., Zolotukhin I.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.rpcardio.online/jour/article/view/2744Aim

Aim: The aim of this meta-analysis and systematic review was to evaluate the possible connection between AF and VTE.

Material and methods

Material and methods. Atrial fibrillation (AF) and atrial flutter (AFL) contribute to intra-atrial blood stasis which leads to thrombus formation with its embolization. There is some evidence that AF can be a risk factor for deep vein thrombosis (DVT) and pulmonary embolism (PE). The following databases were searched: PubMed (MEDLINE), EMBASE, Google Scholar, the Cochrane Central Register of Controlled Trials. The time frame for conducting a systematic literature search ranged from January 1, 1990 to November 1, 2021. The diagnosis of atrial fibrillation had to be confirmed by using ECG. The diagnosis of VTE could be made with Doppler imaging, ventilation/perfusion scan, CT angiography, venography, angiography or autopsy. Only the three studies with 102192 patients meeting the requirement were included in the meta-analysis.

Results

Results. The prevalence of DVT and PE were assessed using incidence rate ratios (IRR) method of the inverse variance random effects model and its 95% confidence interval (CI). The significant association between atrial fibrillation and pulmonary embolism was found (IRR, 4.18 95% Cl 1.958.98). Also there is obvious association between DVT and AF (IRR, 2.97 95% Cl 2.18-4.03).

Conclusion

Conclusion. It can be concluded that the increased risk of developing VTE is associatedwith concomitant AF.

Цель

Цель. Оценить возможную связь между фибрилляцией предсердий (ФП) и риском развития венозных тромбоэмболических осложнений (ВТЭО).

Материал и методы

Материал и методы. Поиск литературы производился в базах данных PubMed (MEDLINE), EMBASE, Google Scholar, центральном регистре контролируемых клинических исследований Кокрейн в период с 1 января 1990 г. по 1 ноября 2021 г. Было включено три исследования с участием 102192 пациентов, которым диагноз ФП был установлен при регистрации электрокардиограммы, а диагноз ВТЭО был подтвержден с помощью ультразвуковой допплерографии вен нижних конечностей, перфузионной сцинтиграфии легких, КТ-ангиографии, флебографии, ангиографии и данных аутопсии. Распространенность тромбоза глубоких вен нижних конечностей и тромбоэмболии легочной артерии оценивались с использованием оценки коэффициентов инцидентности (incidence rate ratios, IRR) методом обратной дисперсии с помощью модели случайных эффектов с 95% доверительным интервалом (ДИ).

Результаты

Результаты. Риск развития ТГВ у пациентов с ФП по сравнению с контрольной группой значимо повышался (IRR 2,97; 95% ДИ 2,18-4,03). Также была обнаружена ассоциация между ФП и ТЭЛА (IRR 4,18; 95% ДИ 1,95-8,98).

Заключение

Заключение. Имеется значимая ассоциация риска развития ВТЭО у пациентов с сопутствующей ФП в общей популяции.

венозные тромбоэмболические осложнениятромбоз глубоких вен нижних конечностейтромбоэмболия легочной артериифибрилляция предсердийvenous thromboembolismdeep vein thrombosispulmonary embolismatrial fibrillationИсследование проведено при поддержке Сеченовского университетаThe study was performed with the support of the Sechenov UniversityReferencesBenjamin EJ, Muntner P, Alonso A, et al. American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics 2019 update: a report from the American Heart Association. Circulation. 2019(10);139:e56e528. DOI:10.1161/CIR.0000000000000659.Benjamin EJ, Muntner P, Alonso A, et al. American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics 2019 update: a report from the American Heart Association. Circulation. 2019(10);139:e56e528. DOI:10.1161/CIR.0000000000000659.Vadmann H, Nielsen PB, Hjortshøj SP, et al. Atrial flutter and thromboembolic risk: a systematic review. Heart. 2015;101(18):1446-55. DOI:10.1136/heartjnl-2015-307550.Vadmann H, Nielsen PB, Hjortshøj SP, et al. Atrial flutter and thromboembolic risk: a systematic review. Heart. 2015;101(18):1446-55. DOI:10.1136/heartjnl-2015-307550.Benjamin EJ, Blaha MJ, Chiuve SE, et al. American Heart Association Statistics C, Stroke Statistics S. Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation. 2017;135(10):e146-e603. DOI:10.1161/CIR.0000000000000485.Benjamin EJ, Blaha MJ, Chiuve SE, et al. American Heart Association Statistics C, Stroke Statistics S. Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation. 2017;135(10):e146-e603. DOI:10.1161/CIR.0000000000000485.Rosamond WD, Folsom AR, Chambless LE, et al. Atherosclerosis Risk in Communities. Coronary heart disease trends in four United States communities. The Atherosclerosis Risk in Communities (ARIC) study 1987-1996. Int J Epidemiol. 2001;30(1):S17-22. DOI:10.1093/ije/30.suppl_1.s17.Rosamond WD, Folsom AR, Chambless LE, et al. Atherosclerosis Risk in Communities. Coronary heart disease trends in four United States communities. The Atherosclerosis Risk in Communities (ARIC) study 1987-1996. Int J Epidemiol. 2001;30(1):S17-22. DOI:10.1093/ije/30.suppl_1.s17.Bikdeli B, Abou Ziki MD, Lip GYH. Pulmonary Embolism and Atrial Fibrillation: Two Sides of the Same Coin? A Systematic Review. Semin Thromb Hemost. 2017;43(8):849-63. DOI:10.1055/s-00361598005.Bikdeli B, Abou Ziki MD, Lip GYH. Pulmonary Embolism and Atrial Fibrillation: Two Sides of the Same Coin? A Systematic Review. Semin Thromb Hemost. 2017;43(8):849-63. DOI:10.1055/s-00361598005.Kukla P, Dlugopolski R, Krupa E, et al. Electrocardiography and prognosis of patients with acute pulmonary embolism. Cardiol J. 2011;18(6):648-53. DOI: 10.5603/cj.2011.0028.Kukla P, Dlugopolski R, Krupa E, et al. Electrocardiography and prognosis of patients with acute pulmonary embolism. Cardiol J. 2011;18(6):648-53. DOI: 10.5603/cj.2011.0028.Barra SN, Paiva LV, Providencia R, et al. Atrial fibrillation in acute pulmonary embolism: prognostic considerations. Emerg Med J. 2013;31(4):308-12. DOI:10.1136/emermed-2012-202089.Barra SN, Paiva LV, Providencia R, et al. Atrial fibrillation in acute pulmonary embolism: prognostic considerations. Emerg Med J. 2013;31(4):308-12. DOI:10.1136/emermed-2012-202089.Gustafsson C, Blombäck M, Britton M, et al. Coagulation factors and the increased risk of stroke in nonvalvular atrial fibrillation. Stroke. 1990;21(1):47-51. DOI:10.1161/01.str.21.1.47.Gustafsson C, Blombäck M, Britton M, et al. Coagulation factors and the increased risk of stroke in nonvalvular atrial fibrillation. Stroke. 1990;21(1):47-51. DOI:10.1161/01.str.21.1.47.Kahn SR, Solymoss S, Flegel KM. Nonvalvular atrial fibrillation: evidence for a prothrombotic state. CMAJ. 1997;157(6):673-81.Kahn SR, Solymoss S, Flegel KM. Nonvalvular atrial fibrillation: evidence for a prothrombotic state. CMAJ. 1997;157(6):673-81.Motoki H, Tomita T, Aizawa K, et al. Coagulation activity is increased in the left atria of patients with paroxysmal atrial fibrillation during the non-paroxysmal period: comparison with chronic atrial fibrillation. Circ J. 2009;73(8):1403-7. DOI:10.1253/circj.cj-09-0008.Motoki H, Tomita T, Aizawa K, et al. Coagulation activity is increased in the left atria of patients with paroxysmal atrial fibrillation during the non-paroxysmal period: comparison with chronic atrial fibrillation. Circ J. 2009;73(8):1403-7. DOI:10.1253/circj.cj-09-0008.Wang CC, Lin CL, Wang GJ, et al. Atrial fibrillation associated with increased risk of venous thromboembolism. A population-based cohort study. Thromb Haemost. 2015;113(1):185-92. DOI:10.1160/TH14-05-0405.Wang CC, Lin CL, Wang GJ, et al. Atrial fibrillation associated with increased risk of venous thromboembolism. A population-based cohort study. Thromb Haemost. 2015;113(1):185-92. DOI:10.1160/TH14-05-0405.Lutsey PL, Norby FL, Alonso A, et al. Atrial fibrillation and venous thromboembolism: evidence of bidirectionality in the Atherosclerosis Risk in Communities Study. J Thromb Haemost. 2018;16(4):670679. DOI:10.1111/jth.13974.Lutsey PL, Norby FL, Alonso A, et al. Atrial fibrillation and venous thromboembolism: evidence of bidirectionality in the Atherosclerosis Risk in Communities Study. J Thromb Haemost. 2018;16(4):670679. DOI:10.1111/jth.13974.Enga KF, Rye-Holmboe I, Hald EM, et al. Atrial fibrillation and future risk of venous thromboembolism: the Tromsø study. J Thromb Haemost. 2015;13(1):10-6. DOI:10.1111/jth.12762.Enga KF, Rye-Holmboe I, Hald EM, et al. Atrial fibrillation and future risk of venous thromboembolism: the Tromsø study. J Thromb Haemost. 2015;13(1):10-6. DOI:10.1111/jth.12762.Noel P, Gregoire F, Capon A, et al. Atrial fibrillation as a risk factor for deep venous thrombosis and pulmonary emboli in stroke patients. Stroke. 1991;22(6):760-2. DOI:10.1161/01.str.22.6.760.Noel P, Gregoire F, Capon A, et al. Atrial fibrillation as a risk factor for deep venous thrombosis and pulmonary emboli in stroke patients. Stroke. 1991;22(6):760-2. DOI:10.1161/01.str.22.6.760.Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Version 6.3.0 [updated March 2022]. The Cochrane Collaboration, 2022 [cited 2021 Nov 10] Available from: https://training.cochrane.org/handbook/current.Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Version 6.3.0 [updated March 2022]. The Cochrane Collaboration, 2022 [cited 2021 Nov 10] Available from: https://training.cochrane.org/handbook/current.Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603-5. DOI:10.1007/s10654010-9491-z.Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603-5. DOI:10.1007/s10654010-9491-z.Bhave PD, Lu X, Girotra S, et al. Race- and sex-related differences in care for patients newly diagnosed with atrial fibrillation. Heart Rhythm. 2015;12(7):1406-12. DOI:10.1016/j.hrthm.2015.03.031.Bhave PD, Lu X, Girotra S, et al. Race- and sex-related differences in care for patients newly diagnosed with atrial fibrillation. Heart Rhythm. 2015;12(7):1406-12. DOI:10.1016/j.hrthm.2015.03.031.Rao SR, Reisman JI, Kressin NR, et al. Explaining racial disparities in anticoagulation control: results from a study of patients at the Veterans Administration. Am J Med Qual. 2015;30(3):214-22. DOI:10.1177/1062860614526282.Rao SR, Reisman JI, Kressin NR, et al. Explaining racial disparities in anticoagulation control: results from a study of patients at the Veterans Administration. Am J Med Qual. 2015;30(3):214-22. DOI:10.1177/1062860614526282.Meschia JF, Merrill P, Soliman EZ, et al. Racial disparities in awareness and treatment of atrial fibrillation: the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study. Stroke. 2010;41(4):581-7. DOI:10.1161/STROKEAHA.109.573907.Meschia JF, Merrill P, Soliman EZ, et al. Racial disparities in awareness and treatment of atrial fibrillation: the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study. Stroke. 2010;41(4):581-7. DOI:10.1161/STROKEAHA.109.573907.Sundbøll J, Hováth-Puhó E, Adelborg K, et al. Risk of arterial and venous thromboembolism in patients with atrial fibrillation or flutter: A nationwide population-based cohort study. Int J Cardiol. 2017;241:182-7. DOI:10.1016/j.ijcard.2017.04.081.Sundbøll J, Hováth-Puhó E, Adelborg K, et al. Risk of arterial and venous thromboembolism in patients with atrial fibrillation or flutter: A nationwide population-based cohort study. Int J Cardiol. 2017;241:182-7. DOI:10.1016/j.ijcard.2017.04.081.Lutsey PL, Norby FL, Zakai NA, et al. Oral anticoagulation therapy and subsequent risk of venous thromboembolism in atrial fibrillation patients. Curr Med Res Opin. 2019;35(5):837-45. DOI:10.1080/03007995.2018.1541445.Lutsey PL, Norby FL, Zakai NA, et al. Oral anticoagulation therapy and subsequent risk of venous thromboembolism in atrial fibrillation patients. Curr Med Res Opin. 2019;35(5):837-45. DOI:10.1080/03007995.2018.1541445.Connolly SJ, Ezekowitz MD, Yusuf S, et al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-51. DOI:10.1056/NEJMoa0905561.Connolly SJ, Ezekowitz MD, Yusuf S, et al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-51. DOI:10.1056/NEJMoa0905561.Patel MR, Mahaffey KW, Garg J, et al. ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883-91. DOI:10.1056/NEJMoa1009638.Patel MR, Mahaffey KW, Garg J, et al. ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883-91. DOI:10.1056/NEJMoa1009638.Granger CB, Alexander JH, McMurray JJV, et al. ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-92. DOI: 10.1056/NEJMoa1107039.Granger CB, Alexander JH, McMurray JJV, et al. ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-92. DOI: 10.1056/NEJMoa1107039.Giugliano RP, Ruff CT, Braunwald E, et al. ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093-104. DOI:10.1056/NEJMoa1310907.Giugliano RP, Ruff CT, Braunwald E, et al. ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093-104. DOI:10.1056/NEJMoa1310907.

The authors declare that there are no conflicts of interest present.